## Quick Facts

**Sector**
Medical Devices

**Product**
Home sleep apnea monitor

**Market Size**
Over $3 billion

**Development Stage**
Revenue generating

**Major Milestones**
ISO 13485:16 certified
Clinically validated
Health Canada approval
CE Mark
First sales

**Executive Chairman**
Geoff Fernie, Ph.D.

**Inventors**
Douglas Bradley, M.D.
Geoff Fernie, Ph.D.
Hisham Alshaer, M.D, Ph.D.

**Inventing Institution**
University Health Network,
Toronto Rehabilitation Institute,
Toronto, Canada

**Contact**
Julie Waras Brogren
Chief Operating Officer
BresoTEC Inc.
555 Richmond St. W, Ste.407
Toronto, ON M5V 3B1
T: 647 985 9239
E: Julie.brogren@bresotec.com

# BresoTEC

## Engineering Sleep. Advancing Health.

Founded in March 2012, BresoTEC's ambition is to develop and commercialize products for the diagnosis and treatment of sleep disorders and related health conditions.

BresoDX® is BresoTEC's first innovative cordless technology that detects breath sounds and head movements to diagnose sleep apnea. The accuracy of BresoDX® versus the in-lab standard test for detecting sleep apnea (polysomnography) has been validated in several clinical trials led by Dr. Hisham Alshaer and Dr. Douglas Bradley of the University Health Network. BresoDX® is the world's first single-user, cordless home sleep test that delivers patient access to a convenient sleep apnea diagnosis without comprising accuracy.

Sleep apnea is a condition characterized by repetitive breathing cessations that disrupt sleep and cause excessive daytime sleepiness. It affects around 10% of the adult population globally. Although treatable, 85% of people with the condition remain undiagnosed. If left untreated, sleep apnea leads to serious health complications, including a 3-4 times higher risk of hypertension, stroke and heart failure. Untreated sleep apnea is also associated with a similar increase in the risk of traffic accidents due to daytime sleepiness. Today, it is the fourth most expensive disease after cancer, diabetes, and coronary heart disease.

The low rate of diagnosis is mainly due to the lack of patient accessibility, cost and inconvenience of undergoing overnight testing in a sleep laboratory, and the complexity of existing home sleep tests. To date, no other sleep apnea diagnostic device has been able to achieve both accuracy and simplicity in a clinically validated technology.

The technology behind BresoDX® was developed by iDAPT Research at Toronto Rehabilitation Institute (TRI), the leading rehabilitation research centre in the world and exclusively licensed from University Health Network (UHN). TRI is part of UHN and is fully affiliated with University of Toronto (UofT).

Seven patent families have been filed in Canada, the US, Europe, Australia and China covering breath monitoring and sleep apnea detection methods, analysis and software algorithm, industrial prototype.

BresoTEC was founded by UHN and MaRS Innovation. The company raised seed funding, Series A and AA from founders, angels and industry investors. The next round of funding will drive global commercialization and pipeline development.